Zyus Life Sciences is focused on providing non-opiod based therapies for the treatment of pain management through the use of cannabinoid-based pharmaceutical drug candidates.
Clinical Trials: Yes.
NEWS & PARTNERSHIPS:
2018
The company acquired certain intellectual property pertaining to a research and development program focused on Interleukin 37 (IL-37).
The company acquired a world-class bio-processing and extraction facility in Saskatoon, Saskatchewan. The facility will be converted into a global-scale world-class dedicated medicinal cannabis oil extraction facility.
2019
The company signed a definitive supply agreement with Up Cannabis for the purchase of dried bulk cannabis from UC.
The company entered into a definitive asset purchase agreement with Ehave to acquire a proprietary health informatics platform.
The company acquired Revon Systems.
The company entered into a 3-year supply agreement of high-grade bulk raw cannabis material with Stevens Green.
2020
The company selected GelCan as its exclusive encapsulation partner for its softgels in the Canadian medical cannabis market.
The company entered into a 3-year supply agreement of high-quality dried cannabis raw material from Pure Sunfarms.
2021
The company partnered with HelloMD to help prospective patients in Canada access independent medical advice. Patients can schedule a free online consultation with a HelloMD licensed healthcare practitioner through Zyus’ website.
The company entered into a multi-year agreement with Australian medical cannabis importer Health House for the sales and distribution of Zyus’ cannabinoid formulations to medical patients through wholesale agents such as pharmacies and hospitals with the agreement covering oils and future product categories.
The company entered into an exclusive, multi-year agreement with Aureuspharma in Portugal for the sales and distribution of Zyus’ medical cannabinoid formulations to Portuguese patients.
2024
The company was awarded US Patent No. 11,963,943 entitled Formulation For Pain Management.
The company received a cannabis drug license from Health Canada pertaining to its processing facility located in Saskatoon, Saskatchewan which is used for the manufacture of pharmaceutical-grade cannabinoid formulations.
The company was granted Patent No. 2022/12127 in South Africa for fixed-dose cannabinoid-based formulations for pain management and other clinically unmet needs.
2025
Trichomylin softgel capsules received patent number: EP 3962473 from the EU Patent Office.